Join to View Full Profile
901 S California AvePalo Alto, CA 94304
Phone+1 650-496-1206
Fax+1 650-496-1107
Dr. Curnutte is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Dana-Farber Cancer InstituteResidency, Pediatrics, 1981 - 1983
Mass General Brigham/Massachusetts General HospitalResidency, Pediatrics, 1979 - 1981
Harvard Medical SchoolClass of 1979
Certifications & Licensure
CA State Medical License 1987 - 2027
MI State Medical License 1983 - 1993
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1988
Publications & Presentations
Abstracts/Posters
- Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with RituximabJohn T. Curnutte, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Dir...John T. Curnutte, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...John T. Curnutte, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Orchard Therapeutics Further Strengthens Board of Directors with Appointment of John Curnutte, M.D., Ph.D.August 30th, 2019
Portola Pharmaceuticals, Inc., a Biopharmaceutical Company, Discovers and Develops Therapeutics for Acute and Chronic Cardiovascular and autoimmune/inflammatory DiseasesJuly 8th, 2019
Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and DevelopmentApril 24th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
